[
    "rolo[2,1-c][1 ,4]benzodiazepin-5-one</p>(1Oj); \n\n T-Methoxy-\u03b4^\u03b4-JS^-hydroxy-S-methoxyphenyO-i-CZ-methyM-ethyl-S-quinolyO-\u03a3- propen-1 -one]pentyl}-oxy-(11 aS)-1 ,2,3, 11 a-5/-/-pyrrolo[2, 1 -c][1 ,4]benzodiazepin-5-one (1Ok);</p>7-Methoxy-8-{6-[3-(4-hydroxy-3-methoxyphenyl)-1-(2-methyl-4-ethyl-3-quinolyl)-2- propen-1 -one]hexyl}-oxy-(11 aS)-1 ,2,3, 11 a-5H-pyrrolo[2, 1 -c][1 ,4]benzodiazepin-5-one (101);</p>In yet another embodiment the structural formula of the representative compounds of chalcone linked pyrrolo[2,1-c][1 ,4]benzodiazepine hybrid are:</p><img id=\"imgf000007_0001\" path=\"imgf000007_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/90008157/WO/20090911/A1/002009/10/99/86/imgf000007_0001.tif\"/></p>Formula 6a-i n = 2, 3,4</p><img id=\"imgf000007_0002\" path=\"imgf000007_0002.tif\" file=\"https://surechembl.org/api/assets/attachment/90008158/WO/20090911/A1/002009/10/99/86/imgf000007_0002.tif\"/></p>Formula 1O a-I n =1 ,2 3, 4,</p>In yet another embodiment the novel chalcone linked pyrrolo[2,1-c][1 ,4] benzodiazepine hybrid exhibits an in vitro anticancer/antitumour activity against human cancer cell lines selected from the group consisting of lung (NCI-H522), cervix (SiHa), breast (MDA-MB-435, Zr-75-1), colon (COLO-205), prostate (DU145, PC3) and oral (DWD, HT1080), melanoma (LOX IMVI, VACC-62) cell lines.</p>In yet another embodiment the concentration of chalcone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrid used for in vitro activity against COLO-205 for IC50 is in the range of 16 to 80\u03bcm, at an exposure period of at least 48 hrs.</p>In yet another embodiment the concentration of chalcone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against DU145 for IC50 is in the range of 16 to 80 \u03bcm, at an exposure period of at least 48 hrs. \n\n In yet another embodiment the concentration of chalcone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against NCI-H522 for IC50 is in the range of 6 to 80 \u03bcm, at an exposure period of at least 48 hrs.</p>In yet another embodiment the concentration of chalcone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against COLO-205 for IC50 is preferably in the range of 19 to 40 \u03bcm, at an exposure period of at least 48 hrs.</p>In yet another embodiment the concentration of chalcone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against LOXIMVI for IC50 is in the range of 5 to 30\u03bcm, at an exposure period of at least 48 hrs. In yet another embodiment the concentration of chalcone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against VACC-62 for IC50 is in the range of 7 to about 54\u03bcm, at an exposure period of at least 48 hrs.</p>In yet another embodiment the concentration of chalcone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against MDA-MB-435 for IC50 is in the range of 9 to about 69\u03bcm, at an exposure period of at least 48 hrs.</p>In yet another embodiment the concentration of chalcone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against SiHa for IC50 is in the range of 29 to about 80\u03bcm, at an exposure period of at least 48 hrs.</p>In yet another embodiment the concentration of chalcone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against Zr-75-1 for IC50 is in the range of 24 to about 80\u03bcm, at an exposure period of at least 48 hrs.</p>In yet another embodiment Chalcone linked pyrrolo[2,1-c][1 ,4]benzodiazepine hybrids as claimed in claims 1&amp;2, wherein the concentration of the compound used for in vitro activity against DWD for IC50 is in the range of 6 to 80\u03bcm, at an exposure period of at least 48 hrs.</p>In yet another embodiment Chalcone linked pyrrolo[2,1-c][1 ,4]benzodiazepine hybrid as claimed in claims 1&amp;2, wherein the concentration of the compound used for in vitro activity against HoP62 for IC50 is in the range of 13 to 40 \u03bcm, at an exposure period of at least 48 hrs. In yet another embodiment Chalcone linked pyrrolo[2,1-c][1 ,4]benzodiazepine hybrid as claimed in claims 1&amp;2, wherein the concentration of the compound used for in vitro activity against HT1080 for IC50 is in the range of 6 to 30\u03bcm, at an exposure period of at least 48 hrs. \n\n In yet another embodiment Chalcone linked pyrrolo[2,1-c][1 , ^benzodiazepine hybrid as claimed in claims 1&amp;2, wherein the concentration of the compound used for in vitro activity against MCF7 for IC50 is in the range of 27 to about 80\u03bcm, at an exposure period of at least 48 hrs. In yet another embodiment Chalcone linked pyrrolo[2, 1 -c][1 ,4]benzodiazepine hybrid as claimed in claims 1&amp;2, wherein the concentration of the compound used for in vitro activity against PC3 for IC50 is in the range of 9 to about 80\u03bcm, at an exposure period of at least 48 hrs.</p>The present invention further provides a pharmaceutical composition comprising chalcone linked pyrrolo[2, 1 -c][1 ,4]benzodiazepine hybrid, its derivatives, analogues, salts or mixture thereof optionally with pharmaceutically acceptable carriers, adjuvants and additives.</p>In yet another embodiment the chalcone linked pyrrolo[2,1-c][1 ,4]benzo diazepine hybrid used is represented by a general formula 6 and 10</p><img id=\"imgf000009_0001\" path=\"imgf000009_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/90008181/WO/20090911/A1/002009/10/99/86/imgf000009_0001.tif\"/></p>R<sup>1</sup>= hydroxyl; R<sup>2</sup>= hydroxyl, fluorine. n= 2, 3,4</p>Formula 6</p><img id=\"imgf000009_0002\" path=\"imgf000009_0002.tif\" file=\"https://surechembl.org/api/assets/attachment/90008155/WO/20090911/A1/002009/10/99/86/imgf000009_0002.tif\"/>\n n=3, 4, 5, 6 R<sup>1</sup> = methyl , ethyl, phenyl R = methyl Formula 10</p>The present invention further provides a process for the preparation of chalcone linked pyrrolo[2,1-c][1 ,4]benzodiazepine hybrid of formula 6 and 10, \n\n \n<img id=\"imgf000010_0001\" path=\"imgf000010_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/90008165/WO/20090911/A1/002009/10/99/86/imgf000010_0001.tif\"/>\n</p>R<sup>1</sup>= hydroxyl; R<sup>2</sup>= hydroxyl, fluorine. n= 2,3,4 Formula 6</p><img id=\"imgf000010_0002\" path=\"imgf000010_0002.tif\" file=\"https://surechembl.org/api/as"
]